A1CNow Self Check is well-suited for diabetes patients whose doctors recommend they check their A1C four times per year. (This often includes those whose treatment plan has changed, or who are struggling to meet glycemic goals
A1CNow Self Check is well-suited for diabetes patients whose doctors recommend they check their A1C four times per year. (This often includes those whose treatment plan has changed, or who are struggling to meet glycemic goals.2 )
Administer quarterly A1C tests at home
Save time traveling back and forth from in-office visits and lab appointments
Save money on the cost per test
According to a recent study, roughly 60% of people with diabetes struggle to sustain glycemic control over a 3-year period. This puts them at greater risk for developing severe complications like neuropathy, blindness, cardiovascular disease and stroke.1
A1CNow Self Check 4 count box
Easy and Efficient
Displays results in 5 minutes
Requires only a small (5 ?L) fingerstick blood sample
Requires no maintenance
Can be stored at room temperature
Is small, compact, and battery-powered
Is affordable and easy-to-use
Comes in a convenient 4-test pack
Accurate
NGSP-certified
IFCC-traceable
CE-marked for self-test use
CLIA-waived
PTS Diagnostics India Private Limited - Service Provider of cardiac check up service, blood test & covid detection kit in Bengaluru, Karnataka.
Name of Business - PTS Diagnostics India
Nature of Business - Exporter and Service Provider
Legal Status of Firm - Limited Company (Ltd./Pvt.Ltd.)
Annual Turnover - Rs. 2 - 5 Crore
Import Export Code (IEC) - 07169*****
GST Number - 29AAICP6842L1ZQ
PTS Diagnostics is an innovative point-of-care diagnostics solutions provider that partners with patients and healthcare professionals to provide the right information at the right time to make the right decisions. The company’s name represents the three pillars upon which it has built its long-term success: People, Technology and Service.
PTS Diagnostics’ signature products include the CardioChek® lipid analyzer, and the A1CNow® family of products. The CardioChek® family of products have screened more than 120 million patients worldwide while the A1CNow® product line works to enable people to lead healthier lives through ongoing management of diabetes. Together these products help identify individuals with cardiometabolic syndrome, a cluster of conditions that increase risks of developing cardiovascular disease or diabetes.
Reviews
There are no reviews yet.